R.Li, C.Swaelens, F.Vandermijnsbrugge, B.Cantinieaux BSTH Laboratory of haematology, Porte de Hal,

Similar documents
LABORATORY APPROACH TO BLEEDING DISORDERS DR NISHANTH PG 1 ST YEAR DEPARTMENT OF PATHOLOGY

Pearls and Pitfalls in Factor Inhibitor Testing

Laboratory Investigation of Challenging Cases. Laura A. Worfolk, Ph.D Scientific Director, Coagulation

Plasma Testing in the Clinical Coagulation Laboratory: New drugs, new problems.

Laboratory investigation in the Bleeding Patient. Dr Craig Taylor Consultant Haematologist May 2016

Evaluation of Complex Coagulation Cases: Case-Based Illustrations of Important Issues

TSOAC Case Study 1. Question. TSOAC Case Study 1 Continued

LABORATORY APPROCH TO THE BLEEDING PATIENT

Please note that the uses described in the following page(s) have not been approved or cleared by FDA, with respect to the described assay or test.

Coagulation in perspective: Blood management. Objectives

Automated Coagulation Analyser product list 2018

CoaDATA product list valid from

Laboratory Investigation of Challenging Cases. Laura A. Worfolk, Ph.D Scientific Director, Coagulation

General Principles of. Hemostasis. Kristine Krafts, M.D.

The Coagulation Workup In The Office Setting

Diagnosing Haemostasis PRODUCT CATALOG

Clumsy Coagulation Communication

Note: The taller 100 x 13 mm tube is not designed to run on the ACL TOP. Plasma after centrifugation of these tubes must be placed in sample cups.

Critical aspects in routine coagulation testing

Special Coagulation - APC Resistance. DiaPharma Group, Inc. Customer Service: Technical Support:

Coagulation Laboratory: Methods, Standards & Cost Effective Testing Part 1

New Anticoagulants Linda Liu, M.D.

Introduction Hemostasis: Tourniquet Test & Bleeding Time. Hematology-Immunology System Faculty of Medicine Universitas Padjadjaran LOGO

Local vasoconstriction. is due to local spasm of the smooth muscle (symp. reflex) can be maintained by platelet vasoconstrictors

Haemostasis Reagents product list 2018

Coagulation Cascade. TF-VIIa. Tissue Factor + VII. XIIa. Prothrombin. XIa. IXa. VIIIa. Thrombin. XL- Fibrin. XIII Monomer. Fibrinogen.

DOACs: When and how to measure their anticoagulant effect

Using TEG in the ED, OR, and ICU. Don H. Van Boerum, MD, FACS

Schedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK

Development of a Novel Automated Screening Method for Detection of FVIII Inhibitors

Current laboratory practices in the diagnosis and management of haemophilia

73 Coagulation Laboratory: Methods, Standards and Cost Effective Testing (Part 1) Donna Castellone MS, MT(ASCP)SH

The Role Of Point of Care Coagulation Testing (POCCT) in Patient Blood Management. Elham Khalaf Adeli

ROTEM delta. Targeted therapy stops the bleeding. Easy and safe handling Fast therapeutic decisions Advanced diagnostic safety

Reverse the New Anticoagulants? Mitchell J Daley, PharmD, BCPS

SAMPLE. Determination of Coagulation Factor Activities Using the One-Stage Clotting Assay

Activated Protein C Resistance vs Factor V Leiden assay: Which is the most cost effective?

Sysmex Educational Enhancement & Development

Coagulopathy Case-2. Andy Nguyen, M.D. 2009

With Stago, discover an outstanding Routine range

Laboratory Monitoring of Anticoagulation

The partial thromboplastin (cephalin) time test

PROTHROMBIN TIME WHY USE LOW ISI (HIGH SENSITIVITY)

Primary hemostasis. Vascular endothelium Vasoconstriction : local tissue factor, nervous system

Simple screening tests for the diagnosis of isolated

Princess Alexandra Hospital Emergency Department. Clinical Procedure. 1 Introduction

LABORATORY DIAGNOSIS OF BLEEDING DISORDERS

Clinical Procedure. ROTEM Trauma, Resuscitation. Princess Alexandra Hospital Emergency Department. 1 Introduction

UW Medicine Alternative Monitoring for Antithrombotic Agents

Managing Coagulation Abnormalities Linda Liu, M.D.

Emergency and Perioperative Hemostasis Testing: Which Assays Provide Helpful Information. Wayne Chandler, MD Laboratory Medicine Seattle Children s

Basic coagulation applications and case studies

DOAC s and Implications on Laboratory Results. Kandice Kottke-Marchant, MD, PhD Cleveland Clinic

NEW! Introducing Simple, Comprehensive Solutions. of the ACL TM Family. New Members. Innovation. Leadership. Commitment.

SEED Coagulation. Sysmex Educational Enhancement and Development April 2014

Coagulation Mechanisms Dr. Nervana Bayoumy

NEW INITIATIVES. Factor XIII, Fibrinolysis, Heparin. Piet Meijer. ECAT Foundation. Leiden The Netherlands

UK NEQAS FOR BLOOD COAGULATION: Programmi EQAS nel laboratorio di coagulazione

Laboratory Testing Issues for Protein C, Protein S and Antithrombin Assays

Haemostasis. The function of haemostasis is: to prevent blood loss from injured vessels. to stop bleeding. to prevent thrombosis

Sysmex Educational Enhancement and Development No

The Comprehensive and Efficient Solution. for Your Hemostasis Lab. Hemostasis System

Index. Autoimmune thrombocytopenic purpura (AITP), 100, 102, 105, 108, 187 Automated platelet counters, , 108

Disclosure (s) Relevant financial relationship(s) None Off-label usage None Change in slide set You betcha! (YES!) 2015 MFMER slide-1

Principles of Coagulation Testing. Andy Nguyen, MD 8/4/2010

Waterfall/ Cascade Model:1960 s. Coagulation Challenges During the Perioperative Period

QUALITY PROGRAMME MANUAL 2014

Disclosures. Thromboelastography. TEG Methodology. TEG Output. Thromboelastography (TEG): Basics & Clinical Applications

DEPARTMENT OF CLINICAL LABORATORY SCIENCES SCHOOL OF HEALTH TECHNOLOGY AND MANAGEMENT THE UNIVERSITY AT STONY BROOK STONY BROOK, NEW YORK

Suitability of analytical methods for detection of thrombogenic factor XIa in Privigen

Session 1 Topics. Vascular Phase of Hemostasis. Coagulation Pathway. Action of Unfractionated Heparin. Laboratory Monitoring of Anticoagulant Therapy

2015 Catalogue Coagulation

Laboratory testing for Direct Oral Anticoagulants (DOACs): Are we ready?

Hemostasis. by Mohie-Aldien Elsayed

Sysmex CS-2500 Hemostasis System Unrestricted Siemens Healthcare Diagnostics Inc All rights reserved.

QUALITY PROGRAMME MANUAL 2013

Hypercoagulation. CP Conference 11/14/2006

These handouts are only meant as a guide while you follow the presentation on the screen. Sometimes the speaker will change some of the slides.

Evaluation of the Bleeding Patient

How to Maximize Resources, Optimize Quality and Minimize Costs in the Coagulation Laboratory- by the Laboratory Whisperer

Platelet type bleeding: (vwd) - Petechiae, purpura, ecchymoses, bruising - Menorrhagia, hematuria, occult GI bleed - Gingival bleeding, epistaxis

COMPANY WITH QUALITY MANAGEMENT SYSTEM CERTIFIED BY DNV GL = ISO 9001 = Thrombin Generation Assay. Kit Insert

CE Update. Pre-analytical Variables in Coagulation Testing Associated With Diagnostic Errors in Hemostasis

Upon completion of the Clinical Hematology rotation, the MLS student will be able to:

UP AND COMING ANTICOAGULANTS AND HEMOSTASIS AGENTS

Use of ROTEM from the Laboratory Perspective. A/Prof David Roxby SA Pathology

Blood Product Utilization

LVHN Scholarly Works. Lehigh Valley Health Network. Joseph G. Ottinger RPh, MS, MBA, BCPS Lehigh Valley Health Network,

F11 (Human) ELISA Kit

More to Life. Where research becomes the basis of discovering newer ways of alleviating human suffering and empowering an individual with good health.

Coagulation. Coagulation Limited CGL, CGDF Surveys & Anatomic Pathology Education Programs. Coagulation 117

Quality Assurance and Quality Control of Thromboelastography and Rotational Thromboelastometry: The UK NEQAS for Blood Coagulation Experience

Longer acting/extended Half Life Products: Laboratory Monitoring

Factor Concentrates. More is better? Alexander Duncan MD Emory Medical Labs

Acute Traumatic Coagulopathy

2 Thomas G. DeLoughery

LUPUS ANTICOAGULANT LABORATORY CODE NUMBER: 900

DISCLOSURE Elaine Gray, NIBSC

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) DRAFT GUIDELINE ON THE CLINICAL INVESTIGATION OF RECOMBINANT FACTOR VIII AND IX PRODUCTS

Postpartum Haemorrhage make sure you give enough fibrinogen!

Transcription:

Institut J. Bordet Normal with Actin-FS avoids intrinsic pathway factors assays in the presence of an isolated prolongation of (Platelin-LS) without hemorrhagic history R.Li, C.Swaelens, F.Vandermijnsbrugge, B.Cantinieaux BSTH Laboratory of haematology, Porte de Hal, Antwerp Institut Jules Bordet and CHU Saint-Pierre, ULB 23/11/2012

Introduction Coagulometer MDA II Reagent Platelin-LS assays Sensitivity Intrinsic pathway factor deficiency Lupus anticoagulant LA Heparin therapy

Introduction An isolated prolonged paediatric Pre-operative screening Bleeding related Non-bleeding related FVIII, FIX, FXI deficiency FXII or contact factor deficiency, Inhibitor like LA

Introduction An isolated prolonged with Platelin LS with Actin FS A mixing study Prolonged Normal Non corrected Corrected FVIII, FIX, FXI FXII deficiency LA FXII deficiency LA FVIII, FIX, FXI, FXII deficiency

Aim An isolated prolonged with Platelin LS with Actin FS A mixing study Differential diagnosis FVIII, FIX, FXI deficiency Bleeding related Non-bleeding related FXII or contact factor deficiency, Inhibitor like LA

An algorithm for a prolonged At first time a prolonged with Platelin LS with Actin FS and A mixing (1:1 without incubation) Prothrombin time, Fibrinogen and Thrombin time Abnormal PT, Fibrinogen and TT Follow other algorithms Normal PT, Fibrinogen and TT New sample to confirm this prolonged and to continue further investigations

Materials and Methods The quantitative determinations of FVIII, FIX, FXI and FXII were performed in using one stage factor clotting assay in the week. - firstly with Platelin LS in two dilutions, - secondly with Actin FS if a suspicion of a nonspecific inhibitor detected by Platelin LS with a non-parallel curve. LA assays (PTT-LA and drvvt) were done in the week.

Materials and Methods During 4 years, from 2008 to 2011, among 9048 paediatric patients: an isolated prolonged in 308 (3.4%) outpatients in their haemostasis screening before surgical intervention 156 pateints with 161 samples: confirmed this prolongation of Median age: 3 years-old, 1 to 15 years-old including 13 neonatal samples (age < 6 months) Further investigations including :FVIII, FIX, FXI, FXII and LA with the limitation of the plasma volume -- in 140 samples: FVIII, FIX and FXI were performed -- in 131 samples : FVIII, FIX, FXI and FXII were performed -- in 88 samples: LA assays were performed

Materials and Methods cut-off values -- with Platelin LS, with Actin FS and mixing cut-off values were established locally (N=50). -- FVIII, FIX, FXI and F XII 50 % 200% -- LA cut-off values were established according to the international recommendation Statistics Sensitivity, Specificity, Postive Predicitive Value, Negative Predictive Value and p value were analysed by Fisher s exact test

Results With the further investigation of factor clotting and LA assays : Explanation of the prolonged : 101/161 (63%) Factor deficiencies: 43 -- for FVIII, FIX and FXI: 17/140 (12%) -- isolated : 10 -- multiple deficiencies: 7 (5 neonatal cases) -- for FVIII, FIX, FXI and FXII: 31/131 (24%) -- isolated FXII: 26 -- multiple deficiencies : 5 (3 neonatal cases) LA: 88 -- Positive: 64 /88 (73%) -- Negative: 24

Results N=140 (FVIII, FIX and FXI ) N=17 FVIII, FIX, FXI deficiencies N=123 FVIII, FIX, FXI normal Bleeding related Non-bleeding related Table 1 The statistical values of an with Actin FS and a mixing study for the detection of FVIII, FIX or FXI deficiencies by Fisher s exact test. N=140 (FVIII, FIX and FXI ) Factor Deficiencies (N=17) % Sensitivity Specificity PPV NPV P value Prolonged Actin-FS 59 93 53 94 <0,0001 Corrected mixing 59 29 10 84 0,2328 Prolonged Actin-FS and Corrected mixing 29 96 50 91 0,0025

Results N=131 (FVIII, FIX, FXI and FXII) N=43 FVIII, FIX, FXI, FXII deficiencies N=88 FVIII, FIX, FXI, FXII normal Table 2 The statistical values of an with Actin FS and a mixing study for the detection of FVIII, FIX, FXI or FXII deficiencies by Fisher s exact test. N=131 (F VIII, IX, FXI and XII ) Factor Deficiencies (N=43) % Sensitivity Specificity PPV NPV P value Prolonged ActinFS 28 92 63 72 0,0034 Corrected mixing 74 38 37 75 0,1225 Prolonged ActinFS and Corrected mixing 14 95 60 69 0,0634

Results Table 3. The levels of intrinsic pathway factor deficiencies with normal Actin FS Normal Actin FS Factor Deficiencies 16,4-36,2 F VIII F IX F XI F XII secondes % % % % Case 1 33,8 48 Case 2 30,4 41 Case 3 32,7 46 Case 4 33,1 37 Case 5 32,1 38 Case 6 35,4 43 Case 7 34,1 32 24 of 26 cases (92%) normal 22-48

Results N=88 (LA) N=64 Positive LA N=24 Negative LA Table 4. The statistical values of an with Actin-FS and a mixing study for the LA detection. N= 88 (LA) Positive LA (N=64) % Sensitivity Specificity PPV NPV P value Non-corrected mixing 55 88 92 42 0,0003 Normal Actin-FS 94 21 76 56 0,0584 Non-corrected mixing and normal Actin-FS 50 96 97 42 <0,0001 A prolonged with Actin FS was found in 4 of 64 positive LA samples.

Conclusions Face to an isolated prolongation of without hemorrhagic or family history, A normal with Actin-FS permitted: -- to exclude a FVIII, FIX or FXI deficiency lower than 30%, -- to explain an isolated prolonged (Platelin-LS) by either a FXII deficiency or the presence of LA, so it was not necessary to perform the factor clotting assays in this case. A mixing study -- a non-corrected mixing was useful to suggest the presence of LA, -- a corrected mixing was useless to detect a factor deficiency.